ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Qin Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8270-3943; OpenAlex author ID A5043530656. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 3

Hydrogel-mediated mitochondrial reprogramming for inducing cell death: a novel approach to overcoming gemcitabine resistance in pancreatic ductal adenocarcinom… Last author DOI 10.1016/j.mtbio.2025.101940 ↗
Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. Co-author DOI 10.1016/j.ejmech.2022.114116 ↗
Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.1c01535 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yungen Xu · 2 shared papers, 2021–2022 · strength 0.27
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116 ↗
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗
Shihui Huang · 2 shared papers, 2021–2022 · strength 0.27
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116 ↗
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗
Shiqi Wu · 2 shared papers, 2021–2022 · strength 0.27
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116 ↗
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗
Qixin Zhao · 1 shared paper, 2025 · strength 0.25
- Paper Hydrogel-mediated mitochondrial reprogramming for inducing cell death: a novel approach to overcoming gemcitabine resis… DOI 10.1016/j.mtbio.2025.101940 ↗
Shuping Wang · 1 shared paper, 2022 · strength 0.15
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116 ↗
Yu Li · 1 shared paper, 2021 · strength 0.12
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗
Shu-Ping Wang · 1 shared paper, 2021 · strength 0.12
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.